Sofosbuvir & Velpatasvir

Velpaclear

Indication:

Velpaclear is Manufactured by Abbott Pharma. Details - Brand Name - Velpaclear Generic - Sofosbuvir and Velpatasvir Strength - Sofosbuvir 400 Mg and Velpatasvir 100 Mg Form - Tablets Packing - 1 X 28 Manufactured by - Abbott Pharma Sofosbuvir, sold under the brand name Velpaclear among others, is a medication used for the treatment of hepatitis C.[1] It is only recommended with some combination of ribavirin, ledipasvir, Velpatasvir or daclatasvir. Warning: Velpaclear medicine out of the reach and sight of children and away from pets, never share your medicines with others, and use this medication only for the indication prescribed.

The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Guidance and Advice: Velpaclear medicine is a prescription drug and should be used under proper medical guidance and advice. Do not share the Velpaclear medicine with others, since they may be suffering from a problem that is not effectively treated by this drug. If you have questions about the Velpaclear drugs you are taking, check with your doctor / Medical adviser / Nurse / Hospital Institution / Health advisor or pharmacist. Notice: The above information is an educational aid only. It is not intended as medical advice for individual conditions or treatments. Talk to your doctor, nurse or pharmacist before following any medical regimen to see if it is safe and effective for you.


Brand name: Velpaclear

Active Ingeridents: Sofosbuvir-400Mg-Velpatasvir-100Mg

Company Name: Abbott

Package: 28 tabs/bottle

Strength : 400 MG & 100 MG

Sofosbuvir Mechanism of action:

Sofosbuvir Plus Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velapatasvir, an NS5A replication complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3 and 4 HCV infection with different regimens and durations dependent on the HCV genotype. Velpatasvir (formerly GS-5816) is a novel NS5A inhibitor that has potent invitro anti-HCV activity across all genotypes at the picomolar level. The combination of sofosbuvir plus velpatasvir is the first once-daily single-tablet regimen with pangenotypic activity.

Dosage and Administration:

Sofosbuvir With Velpatasvir is available as a coformulated, once-daily single-pill combination of sofosbuvir 400 mg plus velpatasvir 100 mg. The recommended dose is one tablet once daily, taken with or without food.

  • Renal Impairment: For patients with mild to moderate renal impairment, no dosage adjustment of sofosbuvir-velpatasvir is recommended. There are insufficient data regarding the safety and efficacy of sofosbuvir-velpatasvir in patients with severe renal impairment (eGFR less than 30 ml/min/1.73m2) or end-stage renal disease requiring hemodialysis. Accordingly, no dosage recommendation has been given for patients with severe renal impairment or end-stage renal disease requiring dialysis.
  • Hepatic Impairment: For patients with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C), no dosage adjustment for sofosbuvir plus velpatasvir is recommended. For patients with decompensated cirrhosis who are receiving sofosbuvir-velpatasvir and ribavirin, clinical and laboratory monitoring is recommended.

Store:

Sofosbuvir With Velpatasvir room temperature away from moisture and heat.

Warning

Sofosbuvir plus Velpatasvir is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Sofosbuvir Side effects:

The most common Side effects (≥10%, all grades) with Sofosbuvir plus Velpatasvir were headache and fatigue; and when used with Ribavirin in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Precaution:

  • Risk of Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone and Another HCV Direct Acting Antiviral: Amiodarone is not recommended for use with Sofosbuvir plus Velpatasvir due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of Sofosbuvir With Velpatasvir with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with Sofosbuvir plus Velpatasvir as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.